Who Paid My Doc
Ryan Knueppel
Infectious Disease Santa Clara, CA Medical Doctor
NPI 1184896656 CMS profile 1137438
710 Lawrence Expy, The Permanente Medical Group, Inc., Dept. 460, Santa Clara, CA 95051
General payments
$0
Research payments
$7,590
Ownership & investment interest
$0
Research they led as principal investigator
$263,810
Through program year 2021, Ryan Knueppel of Santa Clara, CA is reported in the CMS Open Payments database as having received $0 across 0 general payments and $7,590 in research payments paid to them. Separately, studies naming them as principal investigator received $263,810 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 85th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2021 | Research | $7,590 | 1 |
Prescribing to Medicare patients
Part D · data year 2024 · 8 drugsPart D claims
333
Drug cost
$14,835
Branded share of claims
56.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Typhim Vi Typhoid Vi Polysacch Vaccine | Brand | 56 | $4,760 | |
| Adacel Tdap Diph,pertuss(Acell),tet Vac/Pf | Brand | 53 | $2,703 | |
| Havrix Hepatitis A Virus Vaccine/Pf | Brand | 35 | $2,555 | |
| Atovaquone-Proguanil Hcl Atovaquone/Proguanil Hcl | Brand | 44 | $1,509 | |
| Rifampin | Generic | 14 | $1,430 | |
| Ethambutol Hcl | Generic | 11 | $950 | |
| Azithromycin | Generic | 107 | $818 | |
| Acetazolamide | Generic | 13 | $110 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Infectious Disease in California
Related records
Infectious Disease in California
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.